We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

149 hedge funds and large institutions have $491M invested in Progenics Pharmaceuticals Inc in 2018 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 64 increasing their positions, 32 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 32

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 155 → 149 (-6)

6% less capital invested

Capital invested by funds: $522M → $491M (-$31.1M)

17% less call options, than puts

Call options by funds: $7.33M | Put options by funds: $8.83M

19% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 26

Holders
149
Holders Change
-6
Holders Change %
-3.87%
% of All Funds
3.41%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
21
Increased
64
Reduced
32
Closed
26
Calls
$7.33M
Puts
$8.83M
Net Calls
-$1.51M
Net Calls Change
-$10.3M

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$27.8M
2
RCM
RA Capital Management
Massachusetts
+$23.3M
3
State Street
State Street
Massachusetts
+$18.3M
4
BlackRock
BlackRock
New York
+$14.6M
5
Citadel Advisors
Citadel Advisors
Florida
+$11.5M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$7.87M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$4.44M
3
Morgan Stanley
Morgan Stanley
New York
-$3.32M
4
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
California
-$2.52M
5
PA
Pinnacle Associates
New York
-$1.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
RFA
126
Reilly Financial Advisors
California
$8K – – –
FCMT
127
Founders Capital Management (Texas)
Texas
$6K – – –
TFS
128
TrustCore Financial Services
Tennessee
$6K – – –
LJHT
129
Laurie J. Hall Trustee
$4K – – –
Bank of Montreal
130
Bank of Montreal
Ontario, Canada
$4K +$430 +56 +11%
AG
131
Advisor Group
Arizona
$3K – – –
ASN
132
Advisory Services Network
Georgia
$3K +$3.84K +500 New
Daiwa Securities Group
133
Daiwa Securities Group
Japan
$2K – – –
IA
134
IFP Advisors
Florida
$2K – – –
VIA
135
Vantage Investment Advisors
Pennsylvania
$2K – – –
FHB
136
First Hawaiian Bank
Hawaii
$2K +$2.3K +300 New
APP
137
Avantax Planning Partners
Iowa
$2K +$2.47K +322 New
SF
138
Synovus Financial
Georgia
$2K +$2.56K +333 New
JA
139
JOYN Advisors
Georgia
$1K -$953 -124 -61%
IFAM
140
Institutional & Family Asset Management
Colorado
$1K – – –
GAM
141
Gemmer Asset Management
California
$1K +$123 +16 +12%
WC
142
Whitney & Co
New York
$1K +$807 +105 New
TRCT
143
Tower Research Capital (TRC)
New York
$1K +$1.36K +177 New
BBA
144
Baker Bros. Advisors
New York
– -$7.87M -979,016 Closed
Fuller & Thaler Asset Management
145
Fuller & Thaler Asset Management
California
– -$2.52M -312,800 Closed
Millennium Management
146
Millennium Management
New York
– -$960K -119,350 Closed
CAM
147
ClariVest Asset Management
California
– -$661K -82,200 Closed
ARTA
148
A.R.T. Advisors
New York
– -$646K -80,388 Closed
QIM
149
Quantitative Investment Management
Virginia
– -$615K -76,500 Closed
CHAM
150
Clear Harbor Asset Management
Connecticut
– -$485K -60,330 Closed
3 4 5
6
7

PGNX Hedge Fund Activity: Q3 2018 in Review

149 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2018, worth a combined $491M — down 6% from $522M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of PGNX and 21 opened new positions — a net loss of 5 holders — while 32 trimmed existing stakes and 64 added.

The largest buyer was Armistice Capital, adding an estimated $27.8M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $7.87M sold.

  • 149 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2018, down from 155 in Q2 2018.
  • Funds reported $491M of Progenics Pharmaceuticals Inc stock for Q3 2018, down 6% quarter-over-quarter.
  • 21 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2018 and 26 closed out, a net change of -5 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q3 2018 was Armistice Capital, an estimated $27.8M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q3 2018 was Baker Bros. Advisors, an estimated $7.87M sold.

Based on aggregated 13F filings for Q3 2018.